Cheap salbutamol

A COMMUNITY BASED METHOD TO MONITOR THE FREQUENCY AND NATURE OF PAEDIATRIC ADVERSE DRUG REACTIONS D. Stewart, 1 D. Mccaig, 1 C. Bond, 2 P. J. Helms3 & J. S. Mclay. 1The School of Pharmacy, The Robert Gordon University, and Departments of Medicine and Therapeutics, 2General Practice, and 3Child Health. University of Aberdeen, Aberdeen. Spontaneous suspected adverse drug reaction ADR ; reporting to the Committee on Safety of Medicines by healthcare professionals is the main source of information used for regulatory pharmacovigilance in the UK. However relatively little is known of the frequency and severity of ADRs in the paediatric population, although the limited information available suggests that ADRs account for 1.532.09% of paediatric hospital admissions, that 2.649.3% of paediatric inpatients, and 1.511.1% of children in the community suffer from ADRs. There is a clear need for a comprehensive and accessible means of monitoring ADRs in paediatrics. The aim of this study was to pilot a community based method of ADR monitoring and reporting, suitable for both prescribed and over the counter medicines. Data were collected for 4 weeks in seven community pharmacies in Grampian on children under 12 years old collecting prescriptions for amoxicillin, salbutamol, paracetamol or ibuprofen suspension or purchasing paracetamol or ibuprofen suspension. After obtaining informed consent, the parent was interviewed to determine: age of child, post code, details of study medicines and any other medication being taken. The parent was asked to complete and return a 5 day questionnaire for each of the study medicines, recording dose, frequency of dosing, and possible side effects both in the form of an ADR tick list and in freehand. Ethics approval was obtained from the Grampian Research Ethics Committee. During the study period a total of 360 prescriptions or purchases of the study medication were recorded, of which 312 were suitable for study inclusion and 267 85.5% ; parents agreed to participate in the study. Two-hundred and forty-one 90.3% ; children were prescribed one study medicine, 23 8.6% ; children two, and 3 1.1% ; children three study medicines. One hundred and six parents 40% ; returned a total of 122 completed questionnaires, 95 for 1, 9 for 2, and 3 for 3 medicines ; . There were no significant differences in the distributions of child age and Depcat scores between the responders and non responders. A comprehensive tick list of possible side effects occurring since starting the study medication was completed by each parent guardian. Using the symptom tick list 49.5% of ADRs were reported for amoxicillin, 35.8% for paracetamol, 9.2% for ibuprofen, and 5.5% for salbutamol. The most commonly reported ADRs for amoxicillin were diarrhoea 28.9% ; and tiredness 31.6% ; . Using freehand reporting 15 12.3% ; completed questionnaires reported specific ADRs. Diarrhoea was reported by 10.5% of children prescribed amoxicillin, and 5.5% prescribed paracetamol. Only one off label prescription was identified and this was for salbutamol syrup prescribed to a 2 year old child. No off label prescribing due to age, formulation, or dose was noted. This study demonstrates that a paediatric ADR monitoring system, with wide public access, could be operated via community pharmacies with parental monitoring and reporting of ADRs. Iv. Claims against the Company not acknowledged as debts: a. Income Tax Rs.83.30 crore Previous year Rs.13.47 crore ; . Of the above, Rs.14.95 crore Previous year Rs.3.27 crore ; represents claims where the matters have been decided in the Company's favour and the Income Tax Department has filed further appeals before the Income Tax Appellate Tribunal High Court. The balance represents claims where the Company has filed appeals and expects to succeed, based on decisions in earlier assessment years. b. Sales Tax Rs.0.17 crore Previous year Rs.0.17 crore ; . c. Excise Duty Service Tax Rs.8.63 crore Previous year Rs.4.45 crore ; . Of the above, Rs.5.29 crore Previous year Nil ; represents claims where, based on decisions in earlier years, the Company is of the opinion that the demand is not sustainable. d. Others Rs.1.70 crore Previous year Rs.0.31 crore ; . 5. The Government of India has served demand notices in March 1995 and May 1995 on the Company in respect of six bulk drugs, claiming that an amount of Rs.5.46 crore along with interest due thereon is payable into the DPEA under the Drugs Prices Control ; Order, 1979 on account of alleged unintended benefit enjoyed by the Company. The Company has filed its replies to the notices and has contended that no amount is payable into the DPEA under the Drugs Prices Control ; Order, 1979. 6. The Government of India NPPA ; has served show cause notices on the Company on account of overcharging in respect of Salbutamol, Theophylline, Ciprofloxacin, Cloxacillin, Norfloxacin, Cefadroxil, Trimethoprim and Sulphamethoxazole formulations under the Drugs Prices Control ; Order, 1995. The aggregate demand of the show cause notices received upto July 2003 amounted to Rs.360.75 crore. In response to the writ petition filed by the Company against the aforesaid show cause notices, the Hon'ble High Court of Bombay had upheld the Company's contentions and held that the drugs Norfloxacin, Ciprofloxacin, Theophylline, Salbugamol and Cloxacillin cannot be included under price control and consequently had quashed the above show cause notices. The Government of India had filed an appeal in the Supreme Court of India. The Hon'ble Supreme Court of India by its order dated 1st August 2003 laid down the principles for interpretation of the Drug Policy and has remanded the matter to the Hon'ble High Court of Bombay where the petitions are now pending. The Hon'ble Supreme Court of India had also given liberty to the NPPA to recover 50% of the allegedly overcharged amount. In addition, the Company's writ petition has also challenged the wrongful withholding by the Government of the exemption to Salbutqmol manufactured by the Company on the grounds of Research and Development. The said challenge is pending in the Hon'ble High Court of Bombay, which has granted interlocutory orders regarding the same. With regard to the other drugs in the show cause notices, the Company has also pointed out to the Government that it does not manufacture formulations of Cloxacillin and Cefadroxil and has also pointed out that the Company is following the notified prices in respect of formulations of Trimethoprim and Sulphamethoxazole. In response to a notice issued to the Company by the drug authorities, the Company challenged the same before the Hon'ble High Court of Allahabad which granted interlocutory orders in favour of the Company. Subsequent to the orders of the Hon'ble Supreme Court of India, the NPPA had demanded 50% of the amount mentioned in the original notices. The Company had replied to the demand pointing out that the same were not payable in view of the order of the Hon'ble High Court of Allahabad. Influenza immunization of people capable of transmitting influenza to LTCF residents should be required on an annual basis. This includes all persons carrying on activities within the facility, i.e., employees, students, attending physicians, and both health care and non-health care contract workers and volunteers. Few valid medical contraindications to these vaccines exist. Such medical contraindications must be documented to be considered sufficient grounds, i.e.: influenza vaccine should not be given to people who had an anaphylactic reaction to a previous dose or with known anaphylactic hypersensitivity to eggs manifested as hives, swelling of the mouth and throat, difficulty in breathing, hypotension, and shock. individuals with acute febrile illness usually should not be vaccinated until their symptoms have abated. individuals who are allergic to any of the components of the vaccine. individuals who developed Guillan-Barre within 6 to 8 weeks of a previous influenza vaccination. Drug Administration. The drugs used were salbutamol a 2-AR partial agonist ; , alprenolol a 1 2 antagonist with partial 2 agonist activity; refs. 1921 ; , nadolol and carvedilol both 1 2 antagonist with inverse agonist activity at the 2-AR' refs. 22 and 23 ; . To examine the effects of duration of -AR ligand therapy on the phenotype of the murine model of asthma, the experimental drugs were administered either acutely or chronically to different groups of asthmatic mice. Asthmatic mice on acute therapy were given a single i.v. bolus infusion of either -AR ligand or normal saline on protocol day 28, 15 min before airway responsiveness to methacholine was determined. The doses of carvedilol, nadolol, alprenolol, and salbutamol administered to the mice were 24 mg kg 1, 72 mg kg 1, 72 mg kg 1, and 1.2 mg kg 1, respectively. Asthmatic mice on chronic therapy were treated with -AR ligand from protocol days 1 to 28. Those on -blocker therapy had free access to chow treated with carvedilol, nadolol, or alprenolol at concentrations of 2, 400 ppm, 250 ppm, or 7, 200 ppm, respectively. These concentrations were chosen because they had previously been shown to produce effects in mice 24, 25 ; . The i.v. bolus doses were calculated to approximate the loading dose required to achieve similar blood levels to those obtained at steady-state with chronic treatment. The nontreated asthmatic mice were fed normal chow. Salbutamok was delivered for 28 days at a dose of 0.5 mg kg 1 day 1 by using an osmotic minipump Alzet no. 2004, Durect, Cupertino, CA ; . Animal Preparation, Lung Physiology, and Bronchoalveolar Lavage.
TRADE NAME MEDICAL CONDITION DANGEROUS TREATMENT SUBSTANCE Remicaine Injection Arrhythmia Local Anaesthetic LOCAL ANAESTHETIC Remicard Injection Arrhythmia's LOCAL ANAESTHETIC Renezide Tablets Diuretic DIURETIC Repasma Capsules Asthma Unknown Repotin Injection Bone Marrow Stim EPO Respinol Compound Linctus Coughs Pseudo-Ephedrine Reuibloc injection Local Anaesthetic NO Revaton Syrup Tonic Fencamfamine Rheomacrodex IV Infusion Plasma Expander Plasma Expander Rhinofed Tablets Nasal Congestion EPHED Rinex Diffucaps, Syrup & Paed Syrup Allergy Phenyl-Propanalolamine Ritalin Tablets Stimulant Methyl Phenydate Rolab-Furosemide Tablets Diuretic DIURETIC Rolab-Indapamide Tablets Hypertension Diuretic DIURETIC Rolab-Spironolactone Tablets Diuretic DIURETIC Rondec Syrup Coughs + Colds Unknown Sabax Dopamine Inf Concentrate Stimulant Dobutamine Sabax Furosemide Injection Diuretic DIURETIC Saizen Injection Growth Hormone Somatrodin Salbulin Autohaler Asthma Inhaled Sabutamol Secadrex Tablets Hypertension DIURETIC Sectral Capsules & Injection Angina ARR Hypertension B BETA BLOCKER Sedapain Tablets Pain & Fever CAFFEINE Serevent Disk & Diskhaler, Accuhaler, Inhaler Asthma Inhaled Salmeterol Serophene Tablets Ovulatory Stimulant Clomiphene Servatin Tablets Hypertension DIURETIC Silomat Linctus DA Coughs Clobutinol Occiprenaline Simplene Ophthalmic Solution Ophthalmology Unknown Sinemet Tablets & CR Tablets Parkinsons Stimulant Sinucon Tablets Sinus & Nasal Congestion Caffeine Sinustop Tablets Sinus & Nasal Congestion Unknown Sinustop with Codein Tablets Sinus & Nasal Congestion Unknown Slendoll Tablets Slimming Products ? Slenz Capsules Slimming Products ? Solu-Cortef Injection Cortisone STEROID Solu-Medrol Injection Cortisone STEROID Sosenol Injection Severe Pain PENTAZOCINE Sotacor Injection & Tablets Angina Hypertension & Arrhyth. ETA BLOCKER Sotahexal Tablets Angina Hypertension BETA BLOCKER Spiractin Tablets Diuretic DIURETIC SRM-Rhotard Tablets Severe Pain MORPHINE Steromien Syrup Cortisone STEROID Sublimaze injection Anaesthetic Agent Fentanyl Sudafex Expectorant Coughs + Colds Pseudo-Ephedrine Sulfenta + Forte injection Anaesthetic Agent Sufenta Nil Superbolin Injection Androgen Anabolic Steroids & Androgens Supertest IM Injection Androgen Anabolic Steroids & Androgens Suprefact Injection & Nasal Spray Chemotherapy Tropic Hormone Buserelin Sustanon 250 Ampoules Anabolic Steroid Anabolic Steroids & Androgens Symtofed Tablets & Syrup Nasal Congestion NO Synacthen Depot Injection Tropic Hormone Tetra Cosactide Synarel Gynae preparation NAFARELIN Tamoplex Tablets Hormone Inhibitor TAMOXIFEN 92 PRES. YES YES YES YES YES NO YES YES NO NO NO YES YES YES YES NO YES YES YES NO YES YES NO NO YES YES NO YES YES NO NO NO YES YES YES YES YES YES YES YES YES NO YES YES YES YES YES NO YES YES YES OTHER. A computerized adaptive treatment allocation approach which comes closer to answering the key phase II questions. The questions we need to answer are: Is the drug tolerated at appropriate doses and what are the dose-limiting factors? Is there a strong enough efficacy trend to justify investing in a phase III study? What is the optimal dosage? We may also need to know what size of benefit we should plan to detect, and whether there is any interaction, e.g. with rt-PA? infarct volume first reduces and then begins to rise again, so there is an optimum concentration. Customized dosing is achieved using the repinotan single-use point-of-care test kit, which allows adjustment of the infusion rate to maintain therapeutic plasma repinotan levels. The ASTIN Acute Stroke Therapy by Inhibition of Neutrophils ; trial demonstrates a more useful trial design to determine whether UK-279, 276 The ASTIN trial randomised 966 patients with ischaemic stroke, about 20% of whom were cotreated with rt-PA. At first patients were allocated almost evenly across the UK-279, 276 doses but as the trial progressed enrolment was concentrated near the top dose and in the placebo group suggesting that the drug is not very effective, so that the trial should be stopped after 46 weeks. Slide 10 ; It was clear that patients on tPA did better so the study was sensitive to and alfacalcidol. Position Controlled O2 Neb salbutamol 2.5mg & ipratropium 0.5mg IV Hydrocortison 200mg or Pred 40mg Antibiotics Doxycyline ; IV Aminophylline or Salbutamol. Featured new reads other places darfur: an unforgettable hell on earth member of randomly at blog critics my 9 rules i'm in cinq early adopters bookmarkers most commented this month the loser, nowickedwitch and the no go 34 ; pay for blog comments - monday night mash 34 ; follow me - i paying for comments and calciferol, for instance, salbutamol guaifenesin.
SALBUTAMOL INHALER Presentation 1 pressurised inhaler containing 200 doses of 100mcg salbutamol per actuation. Legal Status P.O.M. Most popular articles from the last 7 days fentora cancer pain drug linked to deaths 14 sep 2007 loneliness is gene deep 14 sep 2007 mobile phones do no harm, uk report 13 sep 2007 us employer health premiums up 1 per cent 12 sep 2007 us life expectancy goes up to 78 years 13 sep 2007 - email print - go back to top of page - write an opinion on this article - view arthritis news - back to latest news headlines - subscribe to our weekly newsletter - worldwide hospitals search contact our news editors for any corrections of factual information, or to contact the editors please use our feedback form and alpha-lipoic.
Mundy's observations excited considerable interest in the potential utility of a class of drugs with proven long term safety for a new purpose, treatment of osteopenia or osteoporosis. The initial analysis in humans of the relationship between HMG coA reductase inhibitors and fractures was carried out on the Study of Osteoporotic Fractures and the Fracture Intervention Trial cohorts. In that report Bauer et al. described a nonsignificant reduction in hip RR 0.30, 95.
Warnings and precautions patients should be instructed on the proper use of health 2000 salvutamol 100 mcg and beclomethasone 50 mcg inhaler, to ensure that the drugs reach the target areas in the lungs and amantadine. This also applied to nebulized ipratropium compared with nebulized salbbutamol and nebulized fenoterol.

Yearly rate of exacerbations and the percentage of symptomfree days were both significantly in favour of formoterol. The largest improvement in effectiveness, in percentage terms, was seen for the reduction in the rate of severe exacerbations. Healthcare resource utilisation results are presented in Table 4. All of the individual resource utilisation variables were lower in the formoterol group than in the salgutamol group; the largest differences were found for the number of hospital days and the number of emergency treatments. The results on total daily healthcare costs generated from the resource utilisation are summarised in Table 5. Although the cost of the study drug was higher in the formoterol group, the additional cost of formoterol was partly offset by reductions in cost resulting from lower utilisation of other asthma medication and of other healthcare resources for both countries. Because of the lower price of salbutamol pMDI than DPI, a comparatively lower part of the study drug costs was offset by the cost of emergency treatments and other healthcare contacts, such as physician visits, for Spain than for Sweden see Figure 1 ; . Thus, for Sweden, the 6% difference in total daily healthcare cost was not statistically significant, but in Spain healthcare cost was estimated to be 20% higher p 0.05 ; with formoterol treatment compared with the cheapest salbutamol pMDI. The total healthcare costs are presented in Figure 2, for all patients as well as for patients according to disease severity. Differences in total healthcare costs according to asthma severity were not significantly different between the two treatment groups for intermittent, mild and severe asthma patients in Sweden, although a difference was observed for moderate patients. Further, it is interesting to note that for Sweden, the healthcare costs were even numerically lower for formoterol in the severe patient group. For Spain, formoterol had significantly higher cost for all severity groups, except for severe patients and amiloride. Was assumed; this led to the conclusion that the fenoterol curve would have been similar to the salbutamol curve if fenoterol had been marketed in one half of the actual dose i.e., 100 ixg per puff ; . Assuming a linear dose-response relation which is the more orthodox approach ; would have resulted in comparability of the curves at a level of about one quarter of the actual dose i.e., 50 xg per puff ; , a dose level which is more compatible with the findings of experimental studies 1 ; . Further doubt is cast on the Saskatchewan doseresponse findings by the observation that, if these were valid, there should have been mortality epidemics in many countries with the major increases in beta agonist sales in recent years. These have not occurred 70 ; . In fact, in Sweden, sick leave, the number of days in hospital, and the national cost of treating asthma all decreased after salbutamol and terbutaline were introduced 71 ; . Similarly, the New Zealand time-trend data are inconsistent with the hypothesis that the epidemic may have been due to a class effect of beta agonists. Mortality fell after salbutamol was introduced in 1969 70 ; , and the switch to regular use of beta agonist aerosols in general ; , and the corresponding rise in sales, occurred in 1979, whereas the sudden epidemic of deaths in young asthmatics commenced in 1976 28 ; . Furthermore, total New Zealand sales of beta agonists increased slightly during 1988-1990, and publicity about the possible hazards of regular use of beta agonists commenced only with the publication of the study of Sears et al. 46 ; in December 1990. Thus, regular use of beta agonists does not appear to account for the sudden New Zealand asthma mortality epidemic which commenced when fenoterol was introduced in 1976 and which ended following warnings about the hazards of fenoterol in mid 1989 28.

Bloodline is a collaborative effort between Cincinnati Children's Hospital Medical Center Hemophilia and Thrombosis Center; the University of Cincinnati Hemophilia Treatment Center; and the Tri-State Bleeding Disorder Foundation. It is published for the bleeding disorders community. The purpose of Bloodline is to provide current information in the ever-changing field of hemophilia and other bleeding disorders to patients and their families. It also offers an additional reference for those persons challenged by other complications of the disease. Comments and articles are welcomed. Send to: Bloodline Editor, Cincinnati Children's Hospital Medical Center, Division of Hematology Oncology, Hemophilia and Thrombosis Center, 3333 Burnet Avenue, Cincinnati, OH 45229, bloodlineeditor cchmc and amiodarone.
Present in the genetic code. The scientists analysed all the possible differences people could have and found that four common differences predicted how people would respond to salbutamol. Medicines now are generally tested on large numbers of people, with researchers looking at the average response of those taking the drug versus those taking placebo. "You'll see responses that are very, very good and some that are bad, " Dr Liggett said. "The FDA says to look at the average response." As a result, he said, some drugs that may be quite useful for a small subset of patients may never become available because they show little or no benefit, or they even harm, on the aggregate. By using examinations of DNA, researchers will be able to find subgroups of patients who benefit from certain drugs even if, on average, most patients show no response. Adult Endocrinology Bring Life Into Balance . Eastern Maine Medical Center seeks a second BC BE endocrinologist to care for adult patients at our Diabetes, Endocrine, and Nutrition Center. Our outstanding team of physicians, mid-level providers, dietitians, nurses, and counselors provide comprehensive services for a regional population of 500, 000. Clinical programs include diabetes treatment and education, treatment for endocrine disorders, medical nutrition therapy, and support for surgical weight loss services. Competitive salary and benefits package. Bangor, an award-winning small city, offers easy access to Maine's spectacular coast, lakes, and mountains. Schools rank among New England's best. Bangor is the regional hub for medicine, the arts, and commerce. For confidential consideration, please contact Ann Homola: Phone 1-207-9737444; Fax 1-207-973-7857; email emmccvs emh and cordarone.
What you, people think is largely a fairy tale to make yourselves feel good; to keep the reputation of this drug high.
How old was the participant when he she first got drunk or used any drugs? and elavil. Errors to the extent possible ; , in order to try to minimize or prevent adverse consequences. The review provides information about: Whether indications for use are supported by appropriate objective findings, diagnosis and or symptom; Presence of side effects, allergies, and interactions with medication and food; The dose, frequency, route of administration and duration of each prescribed medication being appropriate for the resident's age and condition; Potentially significant medication interactions for each resident, such as medication-medication, medication-food, medication herbal substances interactions; Laboratory results as applicable; Outcomes of medication therapy; Recent changes in the resident's condition that may be related to medications. Examples of changes related to medication use that could occur at any age, but are more common in the geriatric population, include: o Altered mental status including delirium or excessive somnolence o Anorexia and or unplanned weight loss, or weight gain; o Gastrointestinal bleeding; o Falls, dizziness, or evidence of impaired coordination; o Urinary retention or incontinence; o New cognitive decline, or worsening of dementia; o Constipation; o Insomnia or sleep disturbance; o Seizure activity; and o Behavioral changes, including increased distressed behavior. In reviewing for irregularities, the pharmacist may identify and document concerns in one or more of the following categories: ii See F329 for additional discussion of irregularities relating to dose, duration, indications for use, monitoring and adverse consequences.

Discount Salbutamol

ESKAZOLE tablets come in blister packs of 56 tablets and bottles of 60 tablets. AUST R 97504 blister pack AUST R 97505 bottle pack This is not all the information that is available on ESKAZOLE Tablets. If you have any more questions or are not sure about anything, ask your doctor or pharmacist. Pharmaceutical companies are not in a position to give people an individual diagnosis or medical advice. Your doctor or pharmacist is the best person to give you the individual advice you need. You may also be able to find out more information about your disease from books, for example in public libraries. This leaflet was prepared on 24 November 2004. The information provided applies only to: ESKAZOLE Tablets. ESKAZOLE is a registered trade mark of the GlaxoSmithKline Group of Companies. 2003 GlaxoSmithKline ESKAZOLE tablets Issue Number 4 and endep and salbutamol, for instance, salbutamol wiki.
Henry Schein, Inc. Henry Schein, Inc. Henry Schein, Inc. Henry Schein, Inc. Henry Schein, Inc. Henry Schein, Inc. Henry Schein, Inc. Henry Schein, Inc. Henry Schein, Inc. Henry Schein, Inc. Henry Schein, Inc. Henry Schein, Inc. Herbalife Herbalife.

New proton pump inhibitor PPI ; were submitted for consideration. Following the Committee's review of the evidence provided, it was noted that there are no therapeutic advantages of PARIET vis--vis other PPIs currently listed on the AHWDBL; therefore, cost became the primary consideration in making a recommendation. As a result, the Committee recommended that only PARIET 10 mg should be added to the AHWDBL as it provided the most attractive cost savings. Specifically, PARIET 10 mg is priced at $0.65 tablet or $1.30 2 x 10mg tablets ; , hence it is less expensive than Pariet 20mg priced at $1.90 tablet, as well as other PPIs currently listed on the AHWDBL and caduet. Aerosol inhaler: each puff from the metered-dose inhaler contains 100 g of salbutamol.

1 of 11 South Hams and West Devon Primary Care Trust PGD No. 7 Guidelines for the Administration of Inhaled Walbutamol Preparations in Airways Reversibility Testing in Asthma and COPD in Primary Care Settings within South Hams and West Devon PCT Re-issued January 2006 Review due September 2007. Validates my conviction that innovative research is possible here in India. At DRF we are committed to the goal of putting our first invention on the world market around the turn of the century. Even as we enjoy the heady emotion that comes from the liberalization of the economy we need to introspect on our final destination and the path that will take us there. The trajectory of innovation is unpredictable and there is risk involved for those who undertake this journey. It takes courage and vision to look beyond todays vicissitudes and find hope. But if we do not seize the moment and challenge our capacities we will remain pygmies in this world of giants. The future belongs, not to those who merely seek opportunity, but to those who create it. Let us have the courage to DO THINGS DIFFERENTLY. Thank you very much. With each dose of the drug blended with a carrier substance, lactose, and contained in a gelatin capsule. The drug is delivered when the gelatin capsule is pierced or split in two. Users have to carry a supply of capsules and load each one as required, which may be a difficult feat in someone experiencing an acute asthma attack or having limited dexterity, as in younger children. The Rotahaler, and its later derivative, the Diskhaler, which contains four or eight doses of individual plastic and foil bubble blister packs of the drug depending on the drug ; , and the Spinhaler operate under two different principles. The Rotahaler and Diskhaler operate on the cyclone principle, whereas Spinhaler capsules are attached to a turbine that rotates on inhalation.36 Powder becomes deposited on various parts of the inhaler and regular cleaning with a brush or scraper is advised. One problem with the older DPIs that use gelatin capsules is that the gelatin can soften at high temperatures and in high humidity, making it harder to pierce. Rotahalers and Diskhalers deliver either salbutamol a short-acting 2-agonist, a bronchodilator ; or beclometasone dipropionate an anti-inflammatory corticosteroid ; . In addition, the Diskhaler can deliver salmeterol a long-acting 2-agonist, a bronchodilator ; and fluticasone. The Spinhaler.